Drugs / CD5CAR-CBNK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07454122 | May 2026 → May 2029 expected | fungal infectious disease | Fundacion Clinic per a la Recerca Biomédica | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD5CAR-CBNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07454122 ↗ |
| Modality | Cell therapy | “Allogeneic natural killer (NK) cells derived from umbilical cord blood (CB) units” NCT07454122 ↗ |
| Target | CD5 | “genetically modified to express a chimeric antigen receptor (CAR) based on the CD5 receptor (CD5CAR)” NCT07454122 ↗ |